New VIBRANT Trial Data on Verekitug for Chronic Nasal Polyps
Placebo-adjusted reductions in endoscopic nasal polyp score reached -1.95 (p < 0.0001) at Week 24 under a worst-observation carried-forward...
First Participants Enrolled in Spryte Medical’s InSyte Trial
Spryte Medical has enrolled the first participants in INSYTE, an FDA-approved IDE study evaluating a neuro-specific intravascular optical coherence...
Pharmala Signs Deal for MDMA PTSD Trial in First Responders
PharmAla Biotech has executed a supply-and-data agreement to provide its cGMP MDMA (LaNeo) for an open-label Phase 2 trial...
CRISPR T-Cell Therapy for Solid Tumors Enters Clinical Trial
T-knife Therapeutics has received European authorization of its Clinical Trial Application to initiate ATLAS, an adaptive, first-in-human, open-label Phase...
Rein Therapeutics Doses First Patient in Phase 2 IPF Trial
Rein Therapeutics has dosed the first patient in a randomized, double-blind, placebo-controlled Phase 2 trial of LTI-03 in idiopathic...
Simcyp Simulation Replaces 10 Human Trials for CML Therapy
FDA accepted physiologically based pharmacokinetic (PBPK) predictions generated with Certara’s Simcyp platform in lieu of at least ten dedicated...
Arcutis Starts Phase 1 ARQ-234 Study for Atopic Dermatitis
Arcutis has enrolled the first participant in ARQ-234-131, a Phase 1a/1b, double-blind, randomized, placebo-controlled, first-in-human study of ARQ-234, a...
Medidata and CRIO Empower Sites, Accelerate Clinical Trials
Near-100% source-to-EDC data accuracy, roughly 90% faster data entry at sites, and adoption across more than 2,500 research sites...
Clearmind Medicine Trial Soars After Safety Board Approval
No serious adverse events were reported and overall tolerability remained favorable in Clearmind Medicine’s second cohort of its Phase...
AIM’s Promising New Ampligen Trial for Pancreatic Cancer
No quantitative efficacy data were disclosed, but AIM ImmunoTech reports positive progression-free survival, overall survival, and safety signals from...